YIH
MCRB icon

Y-Intercept (HK)’s Seres Therapeutics MCRB Stock Holding History

Y-Intercept (HK)’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,180
Closed -$89.5K – 1597
2024
Q2 		$89.5K Buy
+6,180
New +$103K ﹤0.01% 1268
2024
Q1 		– Sell
-3,576
Closed -$100K – 1605
2023
Q4 		$100K Buy
+3,576
New +$93.9K 0.01% 1094
2022
Q3 		– Sell
-716
Closed -$49K – 1149
2022
Q2 		$49K Buy
+716
New +$61.7K 0.01% 752
2021
Q3 		– Sell
-574
Closed -$274K – 806
2021
Q2 		$274K Buy
+574
New +$242K 0.07% 436

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Y-Intercept (HK)'s MCRB Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 6,180 shares — an estimated $89.5K sold.

Y-Intercept (HK) first reported a position in MCRB in Q2 2021 and held it in 4 quarters. The position peaked at $274K in Q2 2021. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • Y-Intercept (HK) reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 6,180 Seres Therapeutics shares in Q3 2024, an estimated $89.5K.
  • Y-Intercept (HK) first reported a position in Seres Therapeutics in Q2 2021 and held it in 4 quarters.
  • Y-Intercept (HK)'s Seres Therapeutics position peaked at $274K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.